Developing In Vivo CAR T Cell Therapies

This chapter discusses the limitations of ex vivo CAR T cell therapeutics and the rationale behind developing in vivo CAR T cell therapies. It explains the process of delivering CAR T cell therapies and highlights the advantages of in vivo technology, which aims to simplify the manufacturing process by delivering the CAR T cells directly to the patient's body. The chapter also presents promising results from a recent experiment with an in vivo drug product targeting CD20.